<DOC>
	<DOCNO>NCT02687646</DOCNO>
	<brief_summary>Sequential administration MSCs obtain adipose tissue effective safe treatment acute graft versus host disease refractory first-line treatment . Furthermore infusion cell produce biological pattern patient relate clinical response .</brief_summary>
	<brief_title>Clinical Trial With MSC Graft Versus Host Disease Treatment</brief_title>
	<detailed_description>Multicenter , open , non -controlled clinical trial . It phase I-II trial ass safety efficacy sequential infusion allogeneic MSCs adipose tissue , expand `` vitro '' platelet lysate treatment patient undergoing hematopoietic stem cell trasplantation , develop refractory graft versus host disease first line treatment . This prospective , multicenter , open patient undergo allogeneic transplantation Spanish hospital , one cohort patient receive four sequential dos MSC .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>1 . Diagnosis ≥ grade II Graft Versus Host Disease refractory firstline treatment . 2 . Having subject hematopoietic Stem Cell Transplantation treatment malignant blood disorder control transplantation . The source may bone marrow cell peripheral blood ( PB ) come family member unrelated donor . 3 . Having transplant myeloablative nonmyeloablative conditioning . 4. normal cardiac function ( EF ≥ 40 % ) without evidence uncontrolled hypertension , congestive heart failure , angina pectoris myocardial infarction within 6 month prior process 5 . Lung function without evidence severe obstructive restrictive lung disease . 6 . Age 18 65 year . 7 . Women childbearing age consider one year last menstrual period undergone surgical sterilization must obtain negative pregnancy test time inclusion study commit use medically approve birth control study . 8. normal cardiac function ( EF ≥ 40 % ) without evidence uncontrolled hypertension , congestive heart failure , angina pectoris myocardial infarction within 6 month prior process . 9 . Signature inform consent 1. uncontrolled blood disorder transplantation progression time inclusion . 2. bacterial , viral , fungal control . 3 . Any circumstance propose trial dissuade medical treatment . Pregnancy , lactation refusal use safe contraceptive measure . 4 . Patients currently participate complete participation clinical trial le 3 month participate clinical trial Advanced Therapies previous time period . 5 . Patients currently participate complete participation clinical trial period shorter 3 month participate clinical trial Advanced Therapies previous time . 6. positive serology Hepatitis B , Hepatitis C AIDS Virus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>